MS Contin with transdermal fentanyl in the treatment of moderate to severe pain in the observation of.doc

 PAGE \* MERGEFORMAT 10 MS Contin with transdermal fentanyl in the treatment of moderate to severe pain in the observation of Abstract Objective To observe MS Contin, and fentanyl transdermal patches of moderate to severe cancer pain in patients with treatment efficacy and toxicity and to evaluate the two drugs in cancer pain in a three-tiered position. Method of randomization for the MS Contin group and transdermal fentanyl group, and statistics for 84 patients with moderate to severe cancer pain in patients with analgesic effects and toxicity. The results of transdermal fentanyl and US-MS Contin for moderate to severe cancer pain can play a good analgesic effect, and the result is basically the same. Adverse reactions, nausea, vomiting, constipation and sleepiness are more common, but the acceptance of transdermal fentanyl in patients treated with nausea, vomiting, constipation, less likely to use MS Contin treatment of patients, the difference with a significant. Conclusion US-MS Contin transdermal fentanyl, the analgesic effect in patients with severe cancer pain roughly the same, but the former’s toxicity was significantly lower than the latter. And the fentanyl transdermal system easy to use, patient compliance is good, especially for the merger of gastrointestinal diseases, especially for those who can not be oral, can be used as oral strong opioid substitution treatment outside. Keywords: transdermal fentanyl; MS Contin; pain; mitigation; adverse reactions Cancer pain is the most common symptoms of cancer patients, one of 50% to 80% of cancer patients have varying degrees of pain [1], the terminally ill as much as 60% ~ 90%, about 30% of patients dying the former still not alleviate the severe pain. Pain not only restricts the activities and reduce appetite, sleep, so that patients will produce anxiety, fear, depression and even suicide. The severity of pain caused by the World Health Organization (WHO) attention, but also dev